Media
News
2024-02-28
Angitia Biopharmaceuticals Completes US$40M Second Close of Series B Extension Financing
Angitia Biopharmaceuticals, a global clinical-stage biotechnology company announces the completion of an additional US$40M Series B Extension financing in January 2024 led by YueKai Health, a market-oriented VC funded by GZHT Technology Holding and managed by Yuekai Capital. Combined with the US$46M Series B Extension financing completed in October 2023, Angitia has now raised US$86M in the Series B Extension.
More……
2023-12-08
Angitia Biopharmaceuticals Announces the First Subject Dosed in a Phase III Registrational Trial of AGA111, a Drug Candidate for Enhancing Spinal Fusion
Guangzhou, China and Woodland Hills, California, USA – December 8th, 2023, Angitia Biopharmaceuticals, a global clinical-stage biotechnology company, announced today that the first subject has been successfully dosed in a Phase III registrational clinical trial of AGA111.
More……
2023-10-19
Angitia Biopharmaceuticals Announces Completion of $46M Series B Extension Financing
October 19, 2023 - Angitia Biopharmaceuticals, a global clinical-stage biotechnology company focused on the discovery and development of breakthrough therapies that address the unmet medical needs of patients with serious musculoskeletal disease, announced the closing of a US$46M Series B extension financing led by Morningside Group, and syndicated by 3H Health Investment, OrbiMed, Yonghua Capital, Legend Capital, Oriza Holdings and Elikon Venture. The Series B extension financing brings the total size of the funding round to US$170M. Proceeds from the financing will be used to accelerate the global development of Angitia’s innovative drug candidates for musculoskeletal diseases including AGA111, AGA2115 and AGA2118.
More……
2023-10-17
Angitia Biopharmaceuticals Announces the First Subject Dosed in the Phase Ⅰ Trial of AGA2115, a Novel Biologic for the Treatment of Osteogenesis Imperfecta
Woodland Hills, California, USA – 17 Oct 2023 Angitia Biopharmaceuticals, a global clinical-stage biotechnology company focused on the discovery and development of breakthrough therapies that address the unmet medical needs of patients with serious musculoskeletal disease, announced today that the first subject has been successfully dosed in the Phase Ⅰ clinical trial of AGA2115. The First-in-Human (FIH) trial is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of AGA2115, an investigational therapy for the treatment of osteogenesis imperfecta (OI).
More……
2023-10-16
Angitia Announces that NMPA has Granted Phase III IND Approval for AGA111, a Drug Candidate for Spinal Fusion
Guangzhou, China, and Woodland Hills, California, USA –16 Oct 2023: Angitia Biopharmaceuticals, a global clinical-stage biotechnology company focused on the discovery and development of breakthrough therapies that address the unmet medical needs of patients with serious musculoskeletal disease, announced today that National Medicinal Product Administration (NMPA) has approved Angitia Biopharmaceuticals’ Investigational New Drug (IND) application of the Phase III study for AGA111. Angitia has previously announced the encouraging results from AGA111’s Phase I/II trial, which demonstrated excellent safety and preliminary efficacy in lumbar interbody fusion.
More……
2023-10-13
Angitia Biopharmaceuticals Announces Founder and CEO David Ke Has Been Appointed as an Honorary Professor by Hong Kong Baptist University
Dr. David Ke, Founder and CEO of Angitia, has been appointed as an Honorary Professor by Hong Kong Baptist University (HKBU) during the 9th Honorary Professorship Conferment Ceremony-cum-Seminar on October 10th, 2023. This distinction is a recognition of Dr. Ke’s career achievement in drug discovery and development for musculoskeletal diseases, and his contribution to the education of HKBU. Dr. Ke was invited to present Angitia’s most recent research entitled “Targeting WNT Signaling for Discovering and Developing Innovative Therapies for Bone Diseases” following the conferment ceremony. The presentation was focused on unmet medical needs for new drugs in treating serious bone diseases such as osteoporosis and osteogenesis imperfecta and reported Angitia’s most recent efforts in drug discovery and development for osteogenesis imperfecta. The presentation was well received and generated a great level of interest from the audience in continuing the research and development of new therapies for osteoporosis and osteogenesis imperfecta.
More……
2023-08-19
Angitia Announces FDA Clearance of IND Application for AGA2115, Drug Candidate for Osteogenesis Imperfecta
Woodland Hills, California, USA and Guangzhou, Guangdong, China – Angitia Biopharmaceuticals, a global clinical-stage biotechnology company focused on the discovery and development of breakthrough therapies that address the unmet medical needs of patients with serious musculoskeletal disease, announced today that the U.S. Food and Drug Administration (FDA) has cleared Angitia Biopharmaceuticals’ Investigational New Drug (IND) for AGA2115, an investigational therapy for the treatment of osteogenesis imperfecta (OI). The FDA previously granted AGA2115 an Orphan Drug Designation (ODD) and a Rare Pediatric Disease Designation (RPDD).
More……
2023-03-07
Angitia Announcement – New Board Director Appointed
Guangzhou, China and Woodland Hills, USA: Angitia Biopharmaceuticals is delighted to announce the appointment of Mr. David A Piacquad as an Independent Board Director.
More……
2022-09-20
Angitia Biopharmaceuticals Announces Positive Topline Results from AGA111 Phase 1/2 Trial for Spinal Fusion
Guangzhou, Guangdong, China, and Woodland Hills, California, USA: Angitia Biopharmaceuticals (Angitia) today announced the successful conclusion and positive top-line results of a phase 1/2 study entitled ‘A randomized, double-blind, placebo-controlled study to evaluate the safety and preliminary efficacy of a single intervertebral administration of AGA111 in patients with degenerative disc disease undergoing interbody fusion’. The results from this trial demonstrated an excellent safety profile and preliminary efficacy in increasing fusion rate and improving clinical outcome.
More……
2022-06-29
Angitia Biopharmaceuticals Announces First Subject Dosed in Phase I Clinical Trial of AGA2118
Angitia Biopharmaceuticals Announces First Subject Dosed in Phase I Clinical Trial of AGA2118
More……